Previously, high ACBD3 tumor expression was correlated with poorer overall survival for breast cancer patients irrespective of clinical stage [22], but little is known about the impact of ACBD3 expression in the different breast cancer subtypes, or on either relapse-free or distant metastasis-free survival. This evidence concerns the gene ACBD3 and breast carcinoma.